Dongyang Pharmaceutical (06887.HK) has developed its own glucagon insulin injection, which has been approved for listing in the United States.

Wisdom Financial News App, Dongyangguang Pharmaceuticals (06887.HK) announced that the group's independently developed insulin injection, Ganjing insulin, has been approved for launch by the US Food and Drug Administration. The product is scheduled for shipment in the near future. After successful shipment of the product, the group expects to timely launch the product in the US market for formal commercialization. This milestone will further expand the company's overseas revenue, enhance the global competitiveness of the company's hypoglycemic drugs, and accelerate the implementation of internationalization and industrialization strategies.